# Neuraxis, INC: financial statements, quarterly

NRXS · NYSE · CIK 1933567 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nrxs.md) · [Financials](/companies/nrxs/financials.md) · [Filings](/companies/nrxs/filings.md) · [Insiders](/companies/nrxs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nrxs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [477](/filings/0001493152-24-044538.md) | [531 d](/filings/0001493152-25-010984.md) | [647](/filings/0001641172-25-009571.md) | [612](/filings/0001641172-25-023100.md) | [667](/filings/0001493152-25-021547.md) | [761 d](/filings/0001493152-26-011505.md) | [896](/filings/0001493152-26-022384.md) | [894](/filings/0001493152-26-036978.md) | [811](/filings/0001493152-25-021547.md) | [968 d](/filings/0001493152-26-011505.md) | [1,608](/filings/0001493152-26-022384.md) | [1,929](/filings/0001493152-26-036978.md) |
| Cost of revenue | $k | [67.3](/filings/0001493152-24-044538.md) | [72.3 d](/filings/0001493152-25-010984.md) | [75.1](/filings/0001641172-25-009571.md) | [73.5](/filings/0001641172-25-023100.md) | [97.1](/filings/0001493152-25-021547.md) | [105 d](/filings/0001493152-26-011505.md) | [139](/filings/0001493152-26-022384.md) | [147](/filings/0001493152-26-036978.md) | [135](/filings/0001493152-25-021547.md) | [142 d](/filings/0001493152-26-011505.md) | [218](/filings/0001493152-26-022384.md) | [273](/filings/0001493152-26-036978.md) |
| Gross profit | $k | [410](/filings/0001493152-24-044538.md) | [459 d](/filings/0001493152-25-010984.md) | [572](/filings/0001641172-25-009571.md) | [538](/filings/0001641172-25-023100.md) | [570](/filings/0001493152-25-021547.md) | [656 d](/filings/0001493152-26-011505.md) | [756](/filings/0001493152-26-022384.md) | [747](/filings/0001493152-26-036978.md) | [676](/filings/0001493152-25-021547.md) | [826 d](/filings/0001493152-26-011505.md) | [1,390](/filings/0001493152-26-022384.md) | [1,656](/filings/0001493152-26-036978.md) |
| Research and development | $k | [45.0](/filings/0001493152-24-044538.md) | [(2.2) d](/filings/0001493152-25-010984.md) | [5.6](/filings/0001641172-25-009571.md) | [54.3](/filings/0001641172-25-023100.md) | [126](/filings/0001493152-25-021547.md) | [138 d](/filings/0001493152-26-011505.md) | [118](/filings/0001493152-26-022384.md) | [115](/filings/0001493152-26-036978.md) | [131](/filings/0001493152-25-021547.md) | [146 d](/filings/0001493152-26-011505.md) | [99.6](/filings/0001493152-26-022384.md) | [274](/filings/0001493152-26-036978.md) |
| Operating income | $k | [(3,022)](/filings/0001493152-24-044538.md) | [(1,623) d](/filings/0001493152-25-010984.md) | [(1,832)](/filings/0001641172-25-009571.md) | [(2,207)](/filings/0001641172-25-023100.md) | [(1,651)](/filings/0001493152-25-021547.md) | [(1,467) d](/filings/0001493152-26-011505.md) | [(2,295)](/filings/0001493152-26-022384.md) | [(1,718)](/filings/0001493152-26-036978.md) | [(2,100)](/filings/0001493152-25-021547.md) | [(1,717) d](/filings/0001493152-26-011505.md) | [(1,741)](/filings/0001493152-26-022384.md) | [(2,125)](/filings/0001493152-26-036978.md) |
| Interest expense | $k | [103](/filings/0001493152-24-044538.md) | [22.5 d](/filings/0001493152-25-010984.md) | [26.6](/filings/0001641172-25-009571.md) | [80.7](/filings/0001641172-25-023100.md) | [64.7](/filings/0001493152-25-021547.md) | [2.4 d](/filings/0001493152-26-011505.md) | [2.2](/filings/0001493152-26-022384.md) | [13.4](/filings/0001493152-26-036978.md) | [29.7](/filings/0001493152-25-021547.md) | [28.6 d](/filings/0001493152-26-011505.md) | [26.2](/filings/0001493152-26-022384.md) | [19.8](/filings/0001493152-26-036978.md) |
| Net income | $k | [(8,625)](/filings/0001493152-24-044538.md) | [(1,592) d](/filings/0001493152-25-010984.md) | [(2,121)](/filings/0001493152-25-021547.md) | [(2,918)](/filings/0001493152-25-021547.md) | [(1,755)](/filings/0001493152-25-021547.md) | [(1,448) d](/filings/0001493152-26-011505.md) | [(2,279)](/filings/0001493152-26-036978.md) | [(1,690)](/filings/0001493152-26-036978.md) | [(2,123)](/filings/0001493152-25-021547.md) | [(1,709) d](/filings/0001493152-26-011505.md) | [(1,761)](/filings/0001493152-26-036978.md) | [(2,086)](/filings/0001493152-26-036978.md) |
| Diluted EPS | $ per share | [(2.38)](/filings/0001493152-24-044538.md) | not reported | [(0.32)](/filings/0001641172-25-009571.md) | [(0.42)](/filings/0001641172-25-023100.md) | [(0.25)](/filings/0001493152-25-021547.md) | not reported | [(0.33)](/filings/0001493152-26-022384.md) | [(0.22)](/filings/0001493152-26-036978.md) | [(0.24)](/filings/0001493152-25-021547.md) | not reported | [(0.18)](/filings/0001493152-26-022384.md) | [(0.19)](/filings/0001493152-26-036978.md) |
| Basic EPS | $ per share | [(2.38)](/filings/0001493152-24-044538.md) | not reported | [(0.32)](/filings/0001641172-25-009571.md) | [(0.42)](/filings/0001641172-25-023100.md) | [(0.25)](/filings/0001493152-25-021547.md) | not reported | [(0.33)](/filings/0001493152-26-022384.md) | [(0.22)](/filings/0001493152-26-036978.md) | [(0.24)](/filings/0001493152-25-021547.md) | not reported | [(0.18)](/filings/0001493152-26-022384.md) | [(0.19)](/filings/0001493152-26-036978.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [761](/filings/0001493152-24-014832.md) | [78.6](/filings/0001493152-25-010984.md) | [81.8](/filings/0001493152-24-020692.md) | [1,765](/filings/0001493152-24-030875.md) | [261](/filings/0001493152-24-044538.md) | [3,697](/filings/0001493152-26-011505.md) | [2,005](/filings/0001641172-25-009571.md) | [5,988](/filings/0001641172-25-023100.md) | [4,377](/filings/0001493152-25-021547.md) | [4,965](/filings/0001493152-26-036978.md) | [7,079](/filings/0001493152-26-022384.md) | [8,322](/filings/0001493152-26-036978.md) |
| Current assets | $k | [967](/filings/0001493152-24-014832.md) | [243](/filings/0001493152-25-010984.md) | [408](/filings/0001493152-24-020692.md) | [2,112](/filings/0001493152-24-030875.md) | [632](/filings/0001493152-24-044538.md) | [4,266](/filings/0001493152-26-011505.md) | [2,541](/filings/0001641172-25-009571.md) | [6,619](/filings/0001641172-25-023100.md) | [4,988](/filings/0001493152-25-021547.md) | [5,733](/filings/0001493152-26-036978.md) | [8,143](/filings/0001493152-26-022384.md) | [9,414](/filings/0001493152-26-036978.md) |
| Total assets | $k | [1,236](/filings/0001493152-24-014832.md) | [509](/filings/0001493152-25-010984.md) | [946](/filings/0001493152-24-020692.md) | [2,633](/filings/0001493152-24-030875.md) | [1,143](/filings/0001493152-24-044538.md) | [4,758](/filings/0001493152-26-011505.md) | [3,030](/filings/0001641172-25-009571.md) | [7,088](/filings/0001641172-25-023100.md) | [5,776](/filings/0001493152-25-021547.md) | [6,404](/filings/0001493152-26-036978.md) | [8,746](/filings/0001493152-26-022384.md) | [9,996](/filings/0001493152-26-036978.md) |
| Current liabilities | $k | [2,258](/filings/0001493152-24-014832.md) | [1,886](/filings/0001493152-25-010984.md) | [3,816](/filings/0001493152-24-020692.md) | [7,594](/filings/0001493152-24-030875.md) | [2,664](/filings/0001493152-24-044538.md) | [2,433](/filings/0001493152-26-011505.md) | [2,101](/filings/0001641172-25-009571.md) | [2,347](/filings/0001641172-25-023100.md) | [3,147](/filings/0001493152-25-021547.md) | [2,792](/filings/0001493152-26-036978.md) | [2,814](/filings/0001493152-26-022384.md) | [3,096](/filings/0001493152-26-036978.md) |
| Total liabilities | $k | [2,297](/filings/0001493152-24-014832.md) | [1,913](/filings/0001493152-25-010984.md) | [4,130](/filings/0001493152-24-020692.md) | [7,892](/filings/0001493152-24-030875.md) | [2,937](/filings/0001493152-24-044538.md) | [2,690](/filings/0001493152-26-011505.md) | [2,771](/filings/0001641172-25-009571.md) | [2,835](/filings/0001641172-25-023100.md) | [3,491](/filings/0001493152-25-021547.md) | [3,005](/filings/0001493152-26-036978.md) | [2,998](/filings/0001493152-26-022384.md) | [3,261](/filings/0001493152-26-036978.md) |
| Long-term debt | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $k | [194](/filings/0001493152-23-042163.md) | [148](/filings/0001493152-24-014832.md) | [1,396](/filings/0001493152-24-020692.md) | [4,767](/filings/0001493152-24-030875.md) | [148](/filings/0001493152-24-044538.md) | [154](/filings/0001493152-25-010984.md) | [84.3](/filings/0001641172-25-009571.md) | [121](/filings/0001641172-25-023100.md) | [196](/filings/0001493152-25-021547.md) | [148](/filings/0001493152-26-011505.md) | [101](/filings/0001493152-26-022384.md) | [42.7](/filings/0001493152-26-036978.md) |
| Shareholders' equity | $k | [(1,061)](/filings/0001493152-24-044538.md) | [(1,403)](/filings/0001493152-26-011505.md) | [(3,184)](/filings/0001493152-25-021547.md) | [(5,258)](/filings/0001493152-25-021547.md) | [(1,794)](/filings/0001493152-25-021547.md) | [2,068](/filings/0001493152-26-036978.md) | [258](/filings/0001493152-26-036978.md) | [4,253](/filings/0001493152-26-036978.md) | [2,285](/filings/0001493152-25-021547.md) | [3,399](/filings/0001493152-26-036978.md) | [5,748](/filings/0001493152-26-036978.md) | [6,735](/filings/0001493152-26-036978.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,816) d](/filings/0001493152-24-044538.md) | [(2,630) d](/filings/0001493152-25-010984.md) | [(1,332)](/filings/0001641172-25-009571.md) | [(1,615) d](/filings/0001641172-25-023100.md) | [(1,393) d](/filings/0001493152-25-021547.md) | [(1,758) d](/filings/0001493152-26-011505.md) | [(1,604)](/filings/0001493152-26-022384.md) | [(1,467) d](/filings/0001493152-26-036978.md) | [(1,428) d](/filings/0001493152-25-021547.md) | [(1,934) d](/filings/0001493152-26-011505.md) | [(1,230)](/filings/0001493152-26-022384.md) | [(1,030) d](/filings/0001493152-26-036978.md) |
| Capital expenditure | $k | [2.7 d](/filings/0001493152-24-044538.md) | [16.0 d](/filings/0001493152-25-010984.md) | [14.7](/filings/0001641172-25-009571.md) | [8.7 d](/filings/0001641172-25-023100.md) | [4.4 d](/filings/0001493152-25-021547.md) | [0.0 d](/filings/0001493152-26-011505.md) | [18.0](/filings/0001493152-26-022384.md) | [7.3 d](/filings/0001493152-26-036978.md) | [0.0 d](/filings/0001493152-25-021547.md) | [5.9 d](/filings/0001493152-26-011505.md) | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | period not labelled (2022-09-30) | period not labelled (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.0](/filings/0001493152-23-042163.md) | [2.0](/filings/0001493152-24-020692.md) | [2.0](/filings/0001493152-24-030875.md) | [3.6](/filings/0001493152-24-044538.md) | [6.6](/filings/0001641172-25-009571.md) | [6.9](/filings/0001641172-25-023100.md) | [7.2](/filings/0001493152-25-021547.md) | [7.5](/filings/0001493152-26-022384.md) | [8.5](/filings/0001493152-26-036978.md) | [9.9](/filings/0001493152-25-021547.md) | [10.9](/filings/0001493152-26-022384.md) | [12.1](/filings/0001493152-26-036978.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 12,557,765 at 2026-08-06, from the cover of the [10-Q filed 2026-08-11](/filings/0001493152-26-036978.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.